ERYTHROCYTE-BINDING THERAPEUTICS

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20240279330A1
SERIAL NO

18542152

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)LAUSANNE LAUSANNE VAUD

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dane, Karen Y Auburn, US 19 304
Hubbell, Jeffrey A Chicago, US 173 9467
Kontos, Stephan Belmont, US 20 193

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation